How to appeal a Horizon Blue Cross Blue Shield of New Jersey amyloidosis (cardiac attr + al) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Horizon Blue Cross Blue Shield of New Jersey-specific note: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).

What Horizon Blue Cross Blue Shield of New Jersey's policy requires for amyloidosis (cardiac attr + al)

Cited policy: BCBS Darzalex Faspro + VCd (D-VCd) for Newly-Diagnosed AL Amyloidosis

Adult with newly-diagnosed systemic AL amyloidosis confirmed by tissue biopsy + mass-spec typing OR immunoelectron microscopy identifying kappa or lambda light chains. Mayo 2012/2014 stage I-IIIa (not IIIb in many policies). Measurable hematologic disease (dFLC >=50 mg/L OR involved/uninvolved sFLC ratio abnormal OR M-protein quantifiable). Not eligible for or post ASCT. Hematologist Rx.

How Horizon Blue Cross Blue Shield of New Jersey denies amyloidosis (cardiac attr + al) — and how to counter it

Where Horizon Blue Cross Blue Shield of New Jersey pushes back: 1) Bortezomib-based induction (CyBorD) without daratumumab is sufficient first-line; 2) Reserve daratumumab for relapsed/refractory; 3) Mayo stage IIIb excluded.

Counter-arguments that hold up: ANDROMEDA (Kastritis NEJM 2021) — D-VCd vs VCd in newly-dx AL (n=388): hematologic CR 53% vs 18%, cardiac response 42% vs 22%, MRD-negativity higher with D-VCd. FDA approved Darzalex Faspro D-VCd combination on January 15, 2021 — the ONLY FDA-approved regimen specifically for AL amyloidosis. NCCN Category 1 first-line. CyBorD-without-daratumumab is now considered inferior to D-VCd for daratumumab-eligible patients. Mayo stage IIIb requires individualized review with attention to cardiac safety (slow-titration bortezomib + reduced-dose dexamethasone).

What Horizon Blue Cross Blue Shield of New Jersey typically denies for amyloidosis (cardiac attr + al)

Across Horizon Blue Cross Blue Shield of New Jersey's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:

• OMNIA tier-1 vs tier-2 provider disputes
• Step therapy on biologics
• Behavioral health prior auth
• Out-of-state emergency reductions

Treatments most often denied in this category

These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyndaqel / Vyndamax (tafamidis)
• Attruby (acoramidis)
• Amvuttra (vutrisiran) ATTR-CM
• Onpattro (patisiran)
• Wainua (eplontersen)
• D-VCd for AL

How to submit the appeal to Horizon Blue Cross Blue Shield of New Jersey

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Horizon Blue Cross Blue Shield of New Jersey cited in the denial.
3. File the appeal through Horizon Blue Cross Blue Shield of New Jersey's portal (members: https://www.horizonblue.com ; providers: https://www.horizonblue.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NJ, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Horizon Blue Cross Blue Shield of New Jersey's prior-authorization criteria by drug: Horizon Blue Cross Blue Shield of New Jersey PA criteria on ApprovalHelp.